Literature DB >> 1721333

A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine.

J Fung1, K Abu-Elmagd, A Jain, R Gordon, A Tzakis, S Todo, S Takaya, M Alessiani, A Demetris, O Bronster.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1721333      PMCID： PMC2950613     

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  11 in total

1.  Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications.

Authors:  J J Fung; S Todo; A Jain; J McCauley; M Alessiani; C Scotti; T E Starzl
Journal:  Transplant Proc       Date:  1990-02       Impact factor: 1.066

2.  Pathologic observations in human allograft recipients treated with FK 506.

Authors:  A J Demetris; J J Fung; S Todo; B Banner; T Zerbe; G Sysyn; T E Starzl
Journal:  Transplant Proc       Date:  1990-02       Impact factor: 1.066

3.  Early trials with FK 506 as primary treatment in liver transplantation.

Authors:  S Todo; J J Fung; A J Demetris; A Jain; R Venkataramanan; T E Starzl
Journal:  Transplant Proc       Date:  1990-02       Impact factor: 1.066

4.  Effects of in vivo treatment with FK506 on natural killer cells in rats.

Authors:  P M Markus; M R Van den Brink; B A Luchs; J J Fung; T E Starzl; J C Hiserodt
Journal:  Transplantation       Date:  1991-04       Impact factor: 4.939

5.  FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro.

Authors:  T Kino; H Hatanaka; S Miyata; N Inamura; M Nishiyama; T Yajima; T Goto; M Okuhara; M Kohsaka; H Aoki
Journal:  J Antibiot (Tokyo)       Date:  1987-09       Impact factor: 2.649

6.  Effect of a new immunosuppressive agent, FK 506, on heterotopic cardiac allotransplantation in the rat.

Authors:  T Ochiai; K Nakajima; M Nagata; T Suzuki; T Asano; T Uematsu; T Goto; S Hori; T Kenmochi; T Nakagoori
Journal:  Transplant Proc       Date:  1987-02       Impact factor: 1.066

7.  A highly sensitive method to assay FK-506 levels in plasma.

Authors:  K Tamura; M Kobayashi; K Hashimoto; K Kojima; K Nagase; K Iwasaki; T Kaizu; H Tanaka; M Niwa
Journal:  Transplant Proc       Date:  1987-10       Impact factor: 1.066

8.  A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin.

Authors:  J J Siekierka; S H Hung; M Poe; C S Lin; N H Sigal
Journal:  Nature       Date:  1989-10-26       Impact factor: 49.962

9.  A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase.

Authors:  M W Harding; A Galat; D E Uehling; S L Schreiber
Journal:  Nature       Date:  1989-10-26       Impact factor: 49.962

10.  FK 506 for liver, kidney, and pancreas transplantation.

Authors:  T E Starzl; S Todo; J Fung; A J Demetris; R Venkataramman; A Jain
Journal:  Lancet       Date:  1989-10-28       Impact factor: 79.321
View more
  44 in total

1.  Hepatic and intestinal transplantation at the University of Pittsburgh.

Authors:  K Abu-Elmagd; J Fung; J Reyes; A Rao; A Jain; G Mazariegos; W Marsh; J Madariaga; I Dvorchik; J Bueno; J Rogers; J McMichael; F Dodson; H Vargus; J Martin; A Slivka; V Balan; R Corry; J Rakela; N Murase; J Demetris; S Iwatsuki; T Starzl
Journal:  Clin Transpl       Date:  1998

2.  Vasorelaxation and inhibition of the voltage-operated Ca2+ channels by FK506 in the porcine coronary artery.

Authors:  T Yasutsune; N Kawakami; K Hirano; J Nishimura; H Yasui; K Kitamura; H Kanaide
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

3.  The Pittsburgh randomized trial of tacrolimus compared to cyclosporine for hepatic transplantation.

Authors:  J J Fung; M Eliasziw; S Todo; A Jain; A J Demetris; J P McMichael; T E Starzl; P Meier; A Donner
Journal:  J Am Coll Surg       Date:  1996-08       Impact factor: 6.113

4.  A prospective, randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone in renal transplant patients.

Authors:  R Shapiro; M L Jordan; V P Scantlebury; C Vivas; J J Fung; J McCauley; P Randhawa; A J Demetris; W Irish; A Jain
Journal:  Transplant Proc       Date:  1995-02       Impact factor: 1.066

5.  Association between donor-recipient HLA-DR compatibility and cytomegalovirus hepatitis and chronic rejection in liver transplantation.

Authors:  R Mañez; L T White; S Kusne; M Martin; A J Demetris; T E Starzl; R J Duquesnoy
Journal:  Transplant Proc       Date:  1993-02       Impact factor: 1.066

6.  Randomized trial in primary liver transplantation under immunosuppression with FK 506 or cyclosporine.

Authors:  J Fung; S Todo; K Abu-Elmagd; A Jain; A Tzakis; M Martin; R Selby; O Bronsther; H Doyle; T Gayowski
Journal:  Transplant Proc       Date:  1993-02       Impact factor: 1.066

7.  Fluconazole therapy in transplant recipients receiving FK506.

Authors:  R Mañez; M Martin; D Raman; D Silverman; A Jain; V Warty; I Gonzalez-Pinto; S Kusne; T E Starzl
Journal:  Transplantation       Date:  1994-05-27       Impact factor: 4.939

8.  Long-term insulin requirement after liver transplantation with FK 506 in American veterans.

Authors:  J Tabasco-Minguillan; L Mieles; P Carroll; J Gavaler; D H Van Thiel; T E Starzl
Journal:  Transplant Proc       Date:  1993-02       Impact factor: 1.066

9.  Renal transplantation at the University of Pittsburgh: the impact of FK506.

Authors:  R Shapiro; M Jordan; V P Scantlebury; C Vivas; H A Gritsch; A S Rao; M Trucco; A Zeevi; A J Demetris; P Randhawa
Journal:  Clin Transpl       Date:  1994

10.  A prospective, randomized trial of complete avoidance of steroids in liver transplantation with follow-up of over 7 years.

Authors:  Shawn J Pelletier; Satish N Nadig; David D Lee; John B Ammori; Michael J Englesbe; Randall S Sung; John C Magee; Robert J Fontana; Jeffrey D Punch
Journal:  HPB (Oxford)       Date:  2012-09-28       Impact factor: 3.647
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.